Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Chamoun K, et al. Among authors: rios mb. J Hematol Oncol. 2019 Jan 3;12(1):1. doi: 10.1186/s13045-018-0686-1. J Hematol Oncol. 2019. PMID: 30606227 Free PMC article.
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Jabbour E, et al. Among authors: rios mb. Blood. 2007 Oct 15;110(8):2991-5. doi: 10.1182/blood-2007-01-070045. Epub 2007 Jul 11. Blood. 2007. PMID: 17625066 Free article.
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Jabbour E, et al. Among authors: rios mb. Blood. 2009 Mar 5;113(10):2154-60. doi: 10.1182/blood-2008-04-154344. Epub 2008 Dec 5. Blood. 2009. PMID: 19060245 Free PMC article. Clinical Trial.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Fava C, et al. Among authors: rios mb. Blood. 2009 May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12. Blood. 2009. PMID: 19282457 Free PMC article. Clinical Trial.
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Jabbour E, et al. Among authors: rios mb. Blood. 2011 Feb 10;117(6):1822-7. doi: 10.1182/blood-2010-07-293977. Epub 2010 Oct 28. Blood. 2011. PMID: 21030554 Free PMC article. Clinical Trial.
116 results